An dieser Stelle finden Sie ausgewählte Publikationen aus der Nuklearmedizin

Bluemel C, Cramer A, Grossmann C, Kajdi GW, Malzahn U, Lamp N, Langen HJ, Schmid J, Buck AK, Grimminger HJ, Herrmann K. (2015) iROLL: does 3-D radioguided occult lesion localization improve surgical management in early-stage breast cancer? Eur J Nucl Med Mol Imaging 42:1692-1699.

Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester HJ, Czernin J, Eberlein U, Beykan S, Lapa C, Riedmiller H, Krebs M, Kropf S, Schirbel A, Buck AK, Lassmann M.(2015) Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med 56:855-861.

Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Lückerath K, Pietschmann E, Habringer S, Gerngroß C, Franke K, Rudelius M, Schirbel A, Lapa C, Schwamborn K, Steidle S, Hartmann E, Rosenwald A, Kropf S, Beer AJ, Peschel C, Einsele H, Buck AK, Schwaiger M, Götze K, Wester HJ, Keller U. (2015) In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med 7:477-487.

Eberlein U, Scherthan H, Bluemel C, Peper M, Lapa C, Buck AK, Port M, Lassmann M. DNA Damage in Peripheral Blood Lymphocytes of Thyroid Cancer Patients After Radioiodine Therapy. J Nucl Med.57:173-179.

Lapa C, Lückerath K, Malzahn U, Samnick S, Einsele H, Buck AK, Herrmann K, Knop S. (2014) 18FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation. Oncotarget 5:7381-7391.

Publikationen 2015

Al-Momani E, Israel I, Buck AK, Samnick S. (2015) Improved synthesis of [¹⁸F]FS-PTAD as a new tyrosine-specific prosthetic group for radiofluorination of biomolecules. Appl Radiat Isot 104:136-42.

Baur J, Schedelbeck U, Pulzer A, Bluemel C, Wild V, Fassnacht M, Steger U. (2015) A case report of a solitary pancreatic metastasis of an adrenocortical carcinoma. BMC Surg 15:93.

Bluemel C, Cramer A, Grossmann C, Kajdi GW, Malzahn U, Lamp N, Langen HJ, Schmid J, Buck AK, Grimminger HJ, Herrmann K. (2015) iROLL: does 3-D radioguided occult lesion localization improve surgical management in early-stage breast cancer? Eur J Nucl Med Mol Imaging 42(11):1692-9.

Bluemel C, Herrmann K, Giammarile F, Nieweg OE, Dubreuil J, Testori A, Audisio RA, Zoras O, Lassmann M, Chakera AH, Uren R, Chondrogiannis S, Colletti PM, Rubello D. (2015) EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma. Eur J Nucl Med Mol Imaging 42(11):1750-66.

Bluemel C, Rubello D, Colletti PM, de Bree R, Herrmann K. (2015) Sentinel lymph node biopsy in oral and oropharyngeal squamous cell carcinoma: current status and unresolved challenges. Eur J Nucl Med Mol Imaging 42(9):1469-80.

Chen X, Werner RA, Javadi MS, Maya Y, Decker M, Lapa C, Herrmann K, Higuchi T. (2015) Radionuclide imaging of neurohormonal system of the heart. Theranostics 5(6)545-58.

Drozd VM, Saenko VA, Brenner AV, Drozdovitch V, Pashkevich VI, Kudelsky AV, Demidchik YE, Branovan I, Shiglik N, Rogounovitch TI, Yamashita S, Biko J, Reiners C. (2015) Major Factors Affecting Incidence of Childhood Thyroid Cancer in Belarus after the Chernobyl Accident: Do Nitrates in Drinking Water Play a Role? PLoS ONE(10):9-e0137226.

Eberlein U, Nowak C, Bluemel C, Buck AK, Werner RA, Scherthan H, Lassmann M. (2015) DNA damage in blood lymphocytes in patients after (177)Lu peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 42(11):1739-49.

Eberlein U, Peper M, Fernández M, Lassmann M, Scherthan H. (2015) Calibration of the ?-H2AX DNA double strand break focus assay for internal radiation exposure of blood lymphocytes. PLoS ONE(10):4-e0123174.

Fahey FH, Bom HH, Chiti A, Choi YY, Huang G, Lassmann M, Laurin N, Mut F, Nuñez-Miller R, O'Keeffe D, Pradhan P, Scott AM, Song S, Soni N, Uchiyama M, Vargas L. (2015) Standardization of administered activities in pediatric nuclear medicine: a report of the first nuclear medicine global initiative project, part 1-statement of the issue and a review of available resources. J Nucl Med 56(4):646-51.

Fendler WP, Chalkidis RP, Ilhan H, Knösel T, Herrmann K, Issels RD, Bartenstein P, Cyran CC, Lindner LH, Hacker M. (2015) Evaluation of several FDG PET parameters for prediction of soft tissue tumour grade at primary diagnosis and recurrence. Eur Radiol    25(8):2214-21.

Fendler WP, Lehmann M, Todica A, Herrmann K, Knösel T, Angele MK, Dürr HR, Rauch J, Bartenstein P, Cyran CC, Hacker M, Lindner LH. (2015) PET response criteria in solid tumors predicts progression-free survival and time to local or distant progression after chemotherapy with regional hyperthermia for soft-tissue sarcoma. J Nucl Med 56(4):530-7.

Fluri F, Grünstein D, Cam E, Ungethuem U, Hatz F, Schäfer J, Samnick S, Israel I, Kleinschnitz C, Orts-Gil G, Moch H, Zeis T, Schaeren-Wiemers N, Seeberger P. (2015) Fullerenols and glucosamine fullerenes reduce infarct volume and cerebral inflammation after ischemic stroke in normotensive and hypertensive rats. Exp Neurol 265:142-51.

Foryst-Ludwig A, Kreissl MC, Benz V, Brix S, Smeir E, Ban Z, Januszewicz E, Salatzki J, Grune J, Schwanstecher AK, Blumrich A, Schirbel A, Klopfleisch R, Rothe M, Blume K, Halle M, Wolfarth B, Kershaw EE, Kintscher U. (2015) Adipose Tissue Lipolysis Promotes Exercise-induced Cardiac Hypertrophy Involving the Lipokine C16:1n7-Palmitoleate. J Biol Chem 290(39):23603-15.

Hänscheid H, Fernández M, Lassmann M. (2015) The absorbed dose to blood from blood-borne activity. Phys Med Biol 60(2):741-53.

Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester HJ, Czernin J, Eberlein U, Beykan S, Lapa C, Riedmiller H, Krebs M, Kropf S, Schirbel A, Buck AK, Lassmann M. (2015) Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med 56(6)855-61.

Herrmann K, Czernin J, Wolin EM, Gupta P, Barrio M, Gutierrez A, Schiepers C, Mosessian S, Phelps ME, Allen-Auerbach MS. (2015) Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective. J Nucl Med 56(1):70-5.

Herrmann K, Lapa C, Wester HJ, Schottelius M, Schiepers C, Eberlein U, Bluemel C, Keller U, Knop S, Kropf S, Schirbel A, Buck AK, Lassmann M. (2015) Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor. J Nucl Med 56(3):410-6.

Herrmann K, Queiroz M, Huellner MW, de Galiza Barbosa F, Buck A, Schaefer N, Stolzman P, Veit-Haibach P. (2015) Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT. BMC Cancer 15:1002.

Kläsner B, Buchmann N, Gempt J, Ringel F, Lapa C, Krause BJ. (2015) Early [18F]FET-PET in Gliomas after Surgical Resection: Comparison with MRI and Histopathology. PLoS ONE(10):10-e0141153.

Kletting P, Schimmel S, Hänscheid H, Luster M, Fernández M, Nosske D, Lassmann M, Glatting G. (2015) The NUKDOS software for treatment planning in molecular radiotherapy. Z Med Phys 25(3):264-74.

Kreissl MC, Fassnacht M, Mueller SP. (2015) Systemic treatment of advanced differentiated and medullary thyroid cancer. Overview and practical aspects. Nuklearmedizin 54(3):88-93.

Lapa C, Linsenmann T, Lückerath K, Samnick S, Herrmann K, Stoffer C, Ernestus RI, Buck AK, Löhr M, Monoranu CM. (2015) Tumor-associated macrophages in glioblastoma multiforme-a suitable target for somatostatin receptor-based imaging and therapy? PLoS ONE(10):3-e0122269.

Lapa C, Maya Y, Wagner M, Arias-Loza P, Werner RA, Herrmann K, Higuchi T. (2015)Activation of brown adipose tissue in hypothyroidism. Ann Med 47(7):538-45.

Lapa C, Reiter T, Li X, Werner RA, Samnick S, Jahns R, Buck AK, Ertl G, Bauer WR. (2015) Imaging of myocardial inflammation with somatostatin receptor based PET/CT - A comparison to cardiac MRI. Int J Cardiol 194:44-9.

Lapa C, Werner RA, Schmid JS, Papp L, Zsótér N, Biko J, Reiners C, Herrmann K, Buck AK, Bundschuh RA. (2015) Prognostic value of positron emission tomography-assessed tumor heterogeneity in patients with thyroid cancer undergoing treatment with radiopeptide therapy. Nucl Med Biol 42(4)349-54.

Leonova TA, Drozd VM, Saenko VA, Mine M, Biko J, Rogounovitch TI, Takamura N, Reiners C, Yamashita S. (2015) Bone mineral density in treated at a young age for differentiated thyroid cancer after Chernobyl female patients on TSH-suppressive therapy receiving or not Calcium-D3 supplementation. Endocr J 62(2):173-82.

Linz C, Müller-Richter UD, Buck AK, Mottok A, Ritter C, Schneider P, Metzen D, Heuschmann P, Malzahn U, Kübler AC, Herrmann K, Bluemel C. (2015) Performance of cone beam computed tomography in comparison to conventional imaging techniques for the detection of bone invasion in oral cancer. Int J Oral Maxillofac Surg 44(1):8-15.

Lorenz R, Buck A, Reiners C. (2015) In-patient nuclear medicine therapy in Germany from 2010 to 2012. Analysis of structured quality reports. Nuklearmedizin 54(2):61-8.

Lückerath K, Lapa C, Albert C, Herrmann K, Jörg G, Samnick S, Einsele H, Knop S, Buck AK. (2015) 11C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myeloma. Oncotarget 6(10):8418-29.

Macedo R, Javadi SM, Higuchi T, Carvalho MD, Medeiros Vde F, Azevedo ÍM, Lima FP, Medeiros AC. (2015) Heart and systemic effects of statin pretreatment in a rat model of abdominal sepsis. Assessment by Tc99m-sestamibi biodistribition. Acta Cir Bras 30(6):388-93.

Maffione AM, Lopci E, Bluemel C, Giammarile F, Herrmann K, Rubello D. (2015) Diagnostic accuracy and impact on management of (18)F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review. Eur J Nucl Med Mol Imaging 42(1):152-63.

Pacilio M, Amato E, Lanconelli N, Basile C, Torres LA, Botta F, Ferrari M, Diaz NC, Perez MC, Fernández M, Lassmann M, Gil AV, Cremonesi M. (2015) Differences in 3D dose distributions due to calculation method of voxel S-values and the influence of image blurring in SPECT. Phys Med Biol 60(5):1945-64.

Paschke R, Lincke T, Müller SP, Kreissl MC, Dralle H, Fassnacht M. (2015) The Treatment of Well-Differentiated Thyroid Carcinoma. Dtsch Arztebl Int 112(26):452-8.

Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Lückerath K, Pietschmann E, Habringer S, Gerngroß C, Franke K, Rudelius M, Schirbel A, Lapa C, Schwamborn K, Steidle S, Hartmann E, Rosenwald A, Kropf S, Beer AJ, Peschel C, Einsele H, Buck AK, Schwaiger M, Götze K, Wester HJ, Keller U. (2015) In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med 7(4):477-87.

Porschen R, Buck A, Fischbach W, Gockel I, Görling U, Grenacher L, Hollerbach S, Hölscher A, Körber J, Messmann H, Meyer HJ, Miehlke S, Möhler M, Nöthlings U, Pech U, Schmidberger H, Schmidt M, Stahl M, Stuschke M, Thuss-Patience P, Trojan J, Vanhoefer U, Weimann A, Wenz F, Wullstein C. (2015) S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus. Z Gastroenterol 53(11):1288-347.

Reiter T, Werner RA, Bauer WR, Lapa C. (2015) Detection of cardiac sarcoidosis by macrophage-directed somatostatin receptor 2-based positron emission tomography/computed tomography. Eur Heart J 36(35):2404.

Rowe SP, Gorin MA, Gordetsky J, Ball MW, Pierorazio PM, Higuchi T, Epstein JI, Allaf ME, Javadi MS. (2015) Initial experience using 99mTc-MIBI SPECT/CT for the differentiation of oncocytoma from renal cell carcinoma. Clin Nucl Med 40(4):309-13.

Sbiera S, Leich E, Liebisch G, Sbiera I, Schirbel A, Wiemer L, Matysik S, Eckhardt C, Gardill F, Gehl A, Kendl S, Weigand I, Bala M, Ronchi CL, Deutschbein T, Schmitz G, Rosenwald A, Allolio B, Fassnacht M, Kroiss M. (2015) Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells. Endocrinology 156(11):3895-908.

Schmidt T, Lordick F, Herrmann K, Ott K. (2015) Value of functional imaging by PET in esophageal cancer. J Natl Compr Canc Netw 13(2)239-47.

Thomas L, Lapa C, Bundschuh RA, Polat B, Sonke JJ, Guckenberger M. (2015) Tumour delineation in oesophageal cancer - A prospective study of delineation in PET and CT with and without endoscopically placed clip markers. Radiother Oncol 116(2)269-75.

Tillmanns J, Schneider M, Fraccarollo D, Schmitto JD, Länger F, Richter D, Bauersachs J, Samnick S. (2015) PET imaging of cardiac wound healing using a novel [68Ga]-labeled NGR probe in rat myocardial infarction. Mol Imaging Biol 17(1)76-86.

Verburg FA, Mäder U, Luster M, Hänscheid H, Reiners C. (2015) Determinants of successful ablation and complete remission after total thyroidectomy and ¹³¹I therapy of paediatric differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 42(9):1390-8.

Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, Kulkarni HR, Lassmann M, Klette I, Eiber M, Schwaiger M, Wester HJ. (2015) 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J Nucl Med 56(8):1169-76.

Werner RA, Bluemel C, Allen-Auerbach MS, Higuchi T, Herrmann K. (2015) 68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs. Ann Nucl Med 29(1):1-7.

Werner RA, Bluemel C, Lassmann M, Kudlich T, Higuchi T, Lopci E, Allen-Auerbach M, Colletti PM, Rubello D, Zatelli MC, Herrmann K. (2015) SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors: a comprehensive multidisciplinary team approach. Clin Nucl Med 40(5):e271-7.

Werner RA, Brumberg J, Dierks A, Herrmann K, Biko J, Buck AK, Lapa C. (2015) Paralytic subileus as an adverse effect of amino acid-based nephroprotection in a patient undergoing peptide receptor radionuclide therapy. Clin Nucl Med 40(3):263-4.

Werner RA, Rischpler C, Onthank D, Lapa C, Robinson S, Samnick S, Javadi M, Schwaiger M, Nekolla SG, Higuchi T. (2015) Retention Kinetics of the 18F-Labeled Sympathetic Nerve PET Tracer LMI1195: Comparison with 11C-Hydroxyephedrine and 123I-MIBG. J Nucl Med 56(9):1429-33.

Werner RA, Schmid JS, Muegge DO, Lückerath K, Higuchi T, Hänscheid H, Grelle I, Reiners C, Herrmann K, Buck AK, Lapa C. (2015) Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment. Medicine (Baltimore) 94(45):e2016.

Wester HJ, Keller U, Schottelius M, Beer A, Philipp-Abbrederis K, Hoffmann F, Šime?ek J, Gerngross C, Lassmann M, Herrmann K, Pellegata N, Rudelius M, Kessler H, Schwaiger M. (2015) Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. Theranostics 5(6):618-30.

Publikationen 2014

Bluemel C, Herrmann K, Kübler A, Buck AK, Geissinger E, Wild V, Hartmann S, Lapa C, Linz C, Müller-Richter U. (2014) Intraoperative 3-D imaging improves sentinel lymph node biopsy in oral cancer. Eur J Nucl Med Mol Imaging 41(12):2257-64.

Bluemel C, Herrmann K, Müller-Richter U, Lapa C, Higuchi T, Wild V, Buck AK, Kübler A, Linz C. (2014) Freehand SPECT-guided sentinel lymph node biopsy in early oral squamous cell carcinoma. Head Neck 36(11):E112-6.

Buder K, Lapa C, Kreissl MC, Schirbel A, Herrmann K, Schnack A, Bröcker EB, Goebeler M, Buck AK, Becker JC. (2014) Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging. BMC Cancer 14:268.

Bundschuh RA, Dinges J, Neumann L, Seyfried M, Zsótér N, Papp L, Rosenberg R, Becker K, Astner ST, Henninger M, Herrmann K, Ziegler SI, Schwaiger M, Essler M. (2014) Textural Parameters of Tumor Heterogeneity in ¹?F-FDG PET/CT for Therapy Response Assessment and Prognosis in Patients with Locally Advanced Rectal Cancer. J Nucl Med 55(6):891-7.

Ceci F, Herrmann K, Castellucci P, Graziani T, Bluemel C, Schiavina R, Vollmer C, Droll S, Brunocilla E, Mazzarotto R, Buck AK, Fanti S. (2014) Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. Eur J Nucl Med Mol Imaging 41(12):2222-31.

Chen DY, Schneider PF, Zhang XS, Luo XY, He ZM, Chen T. (2014) Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies. Exp Clin Endocrinol Diabetes 122(1):1-6.

Graf N, Li Z, Herrmann K, Weh D, Aichler M, Slawska J, Walch A, Peschel C, Schwaiger M, Buck AK, Dechow T, Keller U. (2014) Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma. Onco Targets Ther 7:789-98.

Hänscheid H, Fernández M, Eberlein U, Lassmann M. (2014) Self-irradiation of the blood from selected nuclides in nuclear medicine. Phys Med Biol 59(6):1515-31.

Hänscheid H, Lassmann M, Buck AK, Reiners C, Verburg FA. (2014) The limit of detection in scintigraphic imaging with I-131 in patients with differentiated thyroid carcinoma. Phys Med Biol 59(10):2353-68.

Heger U, Bader F, Lordick F, Burian M, Langer R, Dobritz M, Blank S, Bruckner T, Becker K, Herrmann K, Siewert JR, Ott K. (2014) Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis. Gastric Cancer 17(3):478-88.

Herrmann K, Buck AK, Schuster T, Abbrederis K, Blümel C, Santi I, Rudelius M, Wester HJ, Peschel C, Schwaiger M, Dechow T, Keller U. (2014) Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL. Oncotarget 5(12):4050-9.

Herrmann K, Czernin J, Cloughesy T, Lai A, Pomykala KL, Benz MR, Buck AK, Phelps ME, Chen W. (2014) Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. Neuro-oncol 16(4):603-9.

Isaias IU, Spiegel J, Brumberg J, Cosgrove KP, Marotta G, Oishi N, Higuchi T, Küsters S, Schiller M, Dillmann U, van Dyck CH, Buck A, Herrmann K, Schloegl S, Volkmann J, Lassmann M, Fassbender K, Lorenz R, Samnick S. (2014) Nicotinic acetylcholine receptor density in cognitively intact subjects at an early stage of Parkinson's disease. Front Aging Neurosci 6:13.

Israel I, Richter D, Stritzker J, van Ooschot M, Donat U, Buck AK, Samnick S. (2014) PET imaging with [⁶⁸Ga]NOTA-RGD for prostate cancer: a comparative study with [¹⁸F]fluorodeoxyglucose and [¹⁸F]fluoroethylcholine. Curr Cancer Drug Targets 14(4):371-9.

Karantanis D, Kalkanis D, Czernin J, Herrmann K, Pomykala KL, Bogsrud TV, Subramaniam RM, Lowe VJ, Allen-Auerbach MS. (2014) Perceived misinterpretation rates in oncologic 18F-FDG PET/CT studies: a survey of referring physicians. J Nucl Med    55(12):1925-9.

Krohn T, Hänscheid H, Müller B, Behrendt FF, Heinzel A, Mottaghy FM, Verburg FA. (2014) Maximum dose rate is a determinant of hypothyroidism after 131I therapy of Graves' disease but the total thyroid absorbed dose is not. J Clin Endocrinol Metab    99(11):4109-15.

Lapa C, Linsenmann T, Monoranu CM, Samnick S, Buck AK, Bluemel C, Czernin J, Kessler AF, Homola GA, Ernestus RI, Löhr M, Herrmann K. (2014) Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients. J Nucl Med 55(10):1611-6.

Lapa C, Linz C, Bluemel C, Mottok A, Mueller-Richter U, Kuebler A, Schneider P, Czernin J, Buck AK, Herrmann K. (2014) Three-phase bone scintigraphy for imaging osteoradionecrosis of the jaw. Clin Nucl Med 39(1):21-5.

Lapa C, Lückerath K, Malzahn U, Samnick S, Einsele H, Buck AK, Herrmann K, Knop S. (2014) 18 FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation. Oncotarget 5(17):7381-91.

Lassmann M, Treves ST, EANM/SNMMI Paediatric Dosage Harmonization Working Group , Boellaard R, Bolch W, Borgwardt L, Chiti A, Fahey F, Gelfand M, Lassmann M, Parisi M, Pfluger T, Spottswood S, Treves ST. (2014) Paediatric radiopharmaceutical administration: harmonization of the 2007 EANM paediatric dosage card (version 1.5.2008) and the 2010 North American consensus guidelines. Eur J Nucl Med Mol Imaging 41(5):1036-41.

Li X, Bauer W, Israel I, Kreissl MC, Weirather J, Richter D, Bauer E, Herold V, Jakob P, Buck A, Frantz S, Samnick S. (2014) Targeting P-selectin by gallium-68-labeled fucoidan positron emission tomography for noninvasive characterization of vulnerable plaques: correlation with in vivo 17.6T MRI. Arterioscler Thromb Vasc Biol 34(8):1661-7.

Lorenz R, Samnick S, Dillmann U, Schiller M, Ong MF, Faßbender K, Buck A, Spiegel J. (2014) Nicotinic α4β2 acetylcholine receptors and cognitive function in Parkinson's disease. Acta Neurol Scand 130(3):164-71.

Mencacci NE, Isaias IU, Reich MM, Ganos C, Plagnol V, Polke JM, Bras J, Hersheson J, Stamelou M, Pittman AM, Noyce AJ, Mok KY, Opladen T, Kunstmann E, Hodecker S, Münchau A, Volkmann J, Samnick S, Sidle K, Nanji T, Sweeney MG, Houlden H, Batla A, Zecchinelli AL, Pezzoli G, Marotta G, Lees A, Alegria P, Krack P, Cormier-Dequaire F, Lesage S, Brice A, Heutink P, Gasser T, Lubbe SJ, Morris HR, Taba P, Koks S, Majounie E, Raphael Gibbs J, Singleton A, Hardy J, Klebe S, Bhatia KP, Wood NW, International Parkinson's Disease Genomics Consortium and UCL-exomes consortium. (2014) Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. Brain 137(Pt 9):2480-92.
Ott K, Schmidt T, Lordick F, Herrmann K. (2014) Importance of PET in surgery of esophageal cancer. Chirurg 85(6):505-12.

Richter D, Basse-Lüsebrink TC, Kampf T, Fischer A, Israel I, Schneider M, Jakob PM, Samnick S. (2014) Compressed sensing for reduction of noise and artefacts in direct PET image reconstruction. Z Med Phys 24(1):16-26.

Schneider PF, Biko J, Varazashvili L, Neumann S. (2014) β-Radiation exposure to fingertips after using a trained routine application method during radiosynovectomy. Nucl Med Commun 35(11):1175-8.

Strigari L, Konijnenberg M, Chiesa C, Bardies M, Du Y, Gleisner KS, Lassmann M, Flux G. (2014) The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging 41(10):1976-88.

Sweeney R, Polat B, Samnick S, Reiners C, Flentje M, Verburg FA. (2014) O-(2-[(18)F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy. Ann Nucl Med 28(2)154-62.

Thies ED, Tanase K, Maeder U, Luster M, Buck AK, Hänscheid H, Reiners C, Verburg FA. (2014) The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 41(12):2281-90.

Verburg FA, Mäder U, Grelle I, Visser TJ, Peeters RP, Smit JW, Reiners C. (2014) The thyroid axis 'setpoints' are significantly altered after long-term suppressive LT4 therapy. Horm Metab Res 46(11):794-9.

Verburg FA, Mäder U, Reiners C, Hänscheid H. (2014) Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patients. J Clin Endocrinol Metab 99(12):4487-96.

Werner RA, Bluemel C, Lapa C, Muegge DO, Kudlich T, Buck AK, Herrmann K. (2014) Pretherapeutic estimation of kidney function in patients treated with peptide receptor radionuclide therapy: can renal scintigraphy be safely omitted? Nucl Med Commun 35(11):1143-9.

Wieder HA, Pomykala KL, Benz MR, Buck AK, Herrmann K. (2014) PET tracers in musculoskeletal disease beyond FDG. Semin Musculoskelet Radiol 18(2):123-32.
Wiegering A, Herrmann K, Bluemel C, Buck AK, Germer CT. (2014) Importance of FDG-PET/CT for surgery of rectal cancer. Chirurg 85(6):487-92.

Wurmb T, Kühne CA, Schneider R. (2014) In-hospitaltraumamanagement - radiation emergency and multiple trauma - principals of treatment in the emergency room. Anasthesiol Intensivmed Notfallmed Schmerzther 49(9):556-9.

Yamane T, Park MJ, Richter D, Nekolla SG, Javadi MS, Lapa C, Samnick S, Buck AK, Herrmann K, Higuchi T. (2014) Small-animal PET imaging of isolated perfused rat heart. J Nucl Med 55(3):495-9.

Publikationen 2013

Al-Ibraheem A, Buck AK, Benz MR, Rudert M, Beer AJ, Mansour A, Pomykala KL, Haller B, Juenger H, Scheidhauer K, Schwaiger M, Herrmann K. (2013) (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma. Cancer 119(6):1227-34.

Berger ML, Hammerschmidt F, Qian R, Hahner S, Schirbel A, Stichelberger M, Schibli R, Yu J, Arion VB, Woschek A, Öhler E, Zolle IM. (2013) [(3)H]metyrapol and 4-[(131)i]iodometomidate label overlapping, but not identical, binding sites on rat adrenal membranes. Mol Pharm 10(3):1119-30.

Bluemel C, Lapa C, Mottok A, Hahner S, Herrmann K. (2013) Tumor localization in ectopic Cushing syndrome using combined PET/CT imaging. Clin Nucl Med 38 (9):749-51.

Bluemel C, Schnelzer A, Okur A, Ehlerding A, Paepke S, Scheidhauer K, Kiechle M. (2013) Freehand SPECT for image-guided sentinel lymph node biopsy in breast cancer.

Bundschuh RA, Wendl CM, Weirich G, Eiber M, Souvatzoglou M, Treiber U, Kübler H, Maurer T, Gschwend JE, Geinitz H, Grosu AL, Ziegler SI, Krause BJ. (2013) Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens. Eur J Nucl Med Mol Imaging 40(7):1126-34.

Del Guerra A, Bardies M, Belcari N, Caruana CJ, Christofides S, Erba P, Gori C, Lassmann M, Lonsdale MN, Sattler B, Waddington W. (2013) Curriculum for education and training of medical physicists in nuclear medicine: recommendations from the EANM Physics Committee, the EANM Dosimetry Committee and EFOMP. Phys Med 29(2):139-62.

Dießl S, Verburg F, Biko J, Schryen B, Reiners C, Buck A, Hänscheid H. (2013) Improved follow-up of patients with differentiated thyroid carcinoma. The quantitative detection limit of 131I uptake in diagnostic scans. Nuklearmedizin 52(3):81-7.

Dörr JR, Yu Y, Milanovic M, Beuster G, Zasada C, Däbritz JH, Lisec J, Lenze D, Gerhardt A, Schleicher K, Kratzat S, Purfürst B, Walenta S, Mueller-Klieser W, Gräler M, Hummel M, Keller U, Buck AK, Dörken B, Willmitzer L, Reimann M, Kempa S, Lee S, Schmitt CA. (2013) Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature 501(7467):421-5.

Eberlein U, Lassmann M. (2013) Dosimetry of [⁶⁸Ga]-labeled compounds. Appl Radiat Isot 76:70-4.

Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31(29):3639-46.

Essler M, Wantke J, Mayer B, Scheidhauer K, Bundschuh RA, Haller B, Astner ST, Molls M, Andratschke N. (2013) Positron-emission tomography CT to identify local recurrence in stage I lung cancer patients 1 year after stereotactic body radiation therapy. Strahlenther Onkol 189(6):495-501.

Eur J Nucl Med Mol Imaging 40(11):1656-61.

Fernández M, Hänscheid H, Mauxion T, Bardiès M, Kletting P, Glatting G, Lassmann M. (2013) A fast method for rescaling voxel S values for arbitrary voxel sizes in targeted radionuclide therapy from a single Monte Carlo calculation. Med Phys 40(8):082502.

Frank-Raue K, Machens A, Leidig-Bruckner G, Rondot S, Haag C, Schulze E, Lorenz A, Kreissl MC, Dralle H, Raue F, Schmid KW. (2013) Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma. Thyroid 23 (3):294-300.

Glatting G, Bardiès M, Lassmann M. (2013) Treatment planning in molecular radiotherapy. Z Med Phys 23(4):262-9.

Graf N, Herrmann K, Numberger B, Zwisler D, Aichler M, Feuchtinger A, Schuster T, Wester HJ, Senekowitsch-Schmidtke R, Peschel C, Schwaiger M, Keller U, Dechow T, Buck AK. (2013) [18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner.

Grande E, Kreissl MC, Filetti S, Newbold K, Reinisch W, Robert C, Schlumberger M, Tolstrup LK, Zamorano JL, Capdevila J. (2013) Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. Adv Ther  30(11):945-66.

Hahner S, Kreissl MC, Fassnacht M, Haenscheid H, Bock S, Verburg FA, Knoedler P, Lang K, Reiners C, Buck AK, Allolio B, Schirbel A. (2013) Functional characterization of adrenal lesions using [123I]IMTO-SPECT/CT. J Clin Endocrinol Metab 98(4):1508-18.

Hänscheid H, Canzi C, Eschner W, Flux G, Luster M, Strigari L, Lassmann M. (2013) EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases.

Herrmann K, Dahlbom M, Nathanson D, Wei L, Radu C, Chatziioannou A, Czernin J. (2013) Evaluation of the Genisys4, a bench-top preclinical PET scanner. J Nucl Med    54(7):1162-7.

Higuchi T, Yousefi BH, Kaiser F, Gärtner F, Rischpler C, Reder S, Yu M, Robinson S, Schwaiger M, Nekolla SG. (2013) Assessment of the 18F-labeled PET tracer LMI1195 for imaging norepinephrine handling in rat hearts. J Nucl Med 54(7):1142-6.

Horm Metab Res 45(10):728-35.

Is the image quality of I-124-PET impaired by an automatic correction of prompt gammas? PLoS ONE 8(8):e71729.

Jurowich CF, Rikkala PR, Thalheimer A, Wichelmann C, Seyfried F, Sander V, Kreissl M, Germer CT, Koepsell H, Otto C. (2013) Duodenal-jejunal bypass improves glycemia and decreases SGLT1-mediated glucose absorption in rats with streptozotocin-induced type 2 diabetes. Ann Surg 258(1):89-97.

Kletting P, Schimmel S, Kestler HA, Hänscheid H, Luster M, Fernández M, Bröer JH, Nosske D, Lassmann M, Glatting G. (2013) Molecular radiotherapy: the NUKFIT software for calculating the time-integrated activity coefficient. Med Phys 40(10):102504.

Koehler C, Ginzkey C, Kleinsasser NH, Hagen R, Reiners C, Verburg FA. (2013) Short-term severe thyroid hormone deficiency does not influence sleep parameters. Sleep Breath 17(1):253-8.

Kossert K, Jörg G, Gostomski CL. (2013) Experimental half-life determination of ¹⁷⁶Lu. Appl Radiat Isot 81:140-5.

Kreissl MC, Schirbel A, Fassnacht M, Haenscheid H, Verburg FA, Bock S, Saeger W, Knoedler P, Reiners C, Buck AK, Allolio B, Hahner S. (2013) [¹²³I]Iodometomidate imaging in adrenocortical carcinoma. J Clin Endocrinol Metab 98(7):2755-64.

Lassmann M, Nosske D. (2013) Dosimetry of 223Ra-chloride: dose to normal organs and tissues. Dosimetry of 223Ra-chloride: dose to normal organs and tissues. Eur J Nucl Med Mol Imaging 40(2):207-12.

Li X, Bauer W, Kreissl MC, Weirather J, Bauer E, Israel I, Richter D, Riehl G, Buck A, Samnick S. (2013) Specific somatostatin receptor II expression in arterial plaque: (68)Ga-DOTATATE autoradiographic, immunohistochemical and flow cytometric studies in apoE-deficient mice. Atherosclerosis 230(1):33-9.

Lonsdale MN, Lassmann M. (2013) EANM perspective. Radiat Prot Dosimetry 153(2):166-9.

Lückerath K, Lapa C, Spahmann A, Jörg G, Samnick S, Rosenwald A, Einsele H, Knop S, Buck AK. (2013) Targeting paraprotein biosynthesis for non-invasive characterization of myeloma biology. PLoS ONE(8):12-e84840.

Othman EM, Kreissl MC, Kaiser FR, Arias-Loza PA, Stopper H. (2013) Insulin-mediated oxidative stress and DNA damage in LLC-PK1 pig kidney cell line, female rat primary kidney cells, and male ZDF rat kidneys in vivo. Endocrinology 154(4):1434-43.

Preylowski V, Schlögl S, Schoenahl F, Jörg G, Samnick S, Buck AK, Lassmann M. (2013)

Reiners C, Biko J, Haenscheid H, Hebestreit H, Kirinjuk S, Baranowski O, Marlowe RJ, Demidchik E, Drozd V, Demidchik Y. (2013) Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very high-risk radiation-induced differentiated thyroid carcinoma. J Clin Endocrinol Metab 98(7):3039-48.

Reiners C, Schneider R. (2013) Potassium iodide (KI) to block the thyroid from exposure to I-131: current questions and answers to be discussed. Radiat Environ Biophys 52(2):189-93.

Rendl S, Lapa C, Blümel C, Bundschuh RA, Schneider P. (2013) Decision making for osteoporotic treatment using FRAX or DVO risk algorithms in a clinical setting. J Musculoskelet Neuronal Interact 13(3):339-45.

Rischpler C, Fukushima K, Isoda T, Javadi MS, Dannals RF, Abraham R, Wahl R, Bengel FM, Higuchi T. (2013) Discrepant uptake of the radiolabeled norepinephrine analogues hydroxyephedrine (HED) and metaiodobenzylguanidine (MIBG) in rat hearts. Eur J Nucl Med Mol Imaging 40(7):1077-83.

Verburg FA, Hartmann D, Grelle I, Giovanella L, Buck AK, Reiners C. (2013) Relationship between antithyroglobulin autoantibodies and thyroglobulin recovery rates using different thyroglobulin concentrations in the recovery buffer.

Verburg FA, Mäder U, Tanase K, Thies ED, Diessl S, Buck AK, Luster M, Reiners C. (2013) Life expectancy is reduced in differentiated thyroid cancer patients >= 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J Clin Endocrinol Metab 98(1):172-80.

Verburg FA, Reiners C, Grelle I, Barth H, Fassnacht M, Luster M. (2013) Calcium stimulated calcitonin measurement: a procedural proposal. Exp Clin Endocrinol Diabetes 121(5):318-20.

Verburg FA, Reiners C, Hänscheid H. (2013) Approach to the patient: role of dosimetric RAI Rx in children with DTC. J Clin Endocrinol Metab 98(10):3912-9.

Verburg FA, Sweeney R, Hänscheid H, Dießl S, Israel I, Löhr M, Vince GH, Flentje M, Reiners C, Samnick S. (2013) Patients with recurrent glioblastoma multiforme. Initial experience with p-[(131)I]iodo-L-phenylalanine and external beam radiation therapy. Nuklearmedizin 52(1):36-42.

Publikationen 2012

Angheloiu GO, Hänscheid H, Wen X, Capponi V, Anderson WD, Kellum JA. (2012) Experimental first-pass method for testing and comparing sorbent polymers used in the clearance of iodine contrast materials. Blood Purif 34(1):34-9.

Bundschuh RA, Andratschke N, Dinges J, Duma MN, Astner ST, Brügel M, Ziegler SI, Molls M, Schwaiger M, Essler M. (2012) Respiratory gated [18F]FDG PET/CT for target volume delineation in stereotactic radiation treatment of liver metastases. Strahlenther Onkol 188(7):592-8.

Chen DY, Schneider PF, Zhang XS, He ZM, Chen TH. (2012) Fatality after cardiac arrest in thyrotoxic periodic paralysis due to profound hypokalemia resulting from intravenous glucose administration and inadequate potassium replacement. Thyroid 22(9):969-72.

Chen DY, Schneider PF, Zhang XS, He ZM, Jing J, Chen TH. (2012) Mental health status and factors that influence the course of Graves' disease and antithyroid treatments. Exp Clin Endocrinol Diabetes 120(9):524-8.

Chiesa C, Luster M, Lassmann M. (2012) 4th international symposium on targeted radiotherapy and dosimetry (ISTARD): best ranked abstract publication. Q J Nucl Med Mol Imaging 56(6):485-6.

Diessl S, Holzberger B, Mäder U, Grelle I, Smit JW, Buck AK, Reiners C, Verburg FA. (2012) Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 76(4):586-92.

Giovanella L, Ceriani L, De Palma D, Suriano S, Castellani M, Verburg FA. (2012) Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas. Head Neck 34(5):626-31.

Hahner S, Kreissl MC, Fassnacht M, Haenscheid H, Knoedler P, Lang K, Buck AK, Reiners C, Allolio B, Schirbel A. (2012) [131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma. J Clin Endocrinol Metab 97(3):914-22.

Hänscheid H, Sweeney RA, Flentje M, Buck AK, Löhr M, Samnick S, Kreissl M, Verburg FA. (2012) PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma. Eur J Nucl Med Mol Imaging 39(8):1284-8.

Hempel K, Haenscheid H, Biko J, Hategan M, Kaiser F, Kreissl M, Lorenz R, Samnick S, Schirbel A, Varazashvili L, Verchenya S, Reiners C. (2012) Frequency of transferrin receptor positive reticulocytes (TF-Ret) in blood as an indicator of total-body radiation exposure: a pilot study in nuclear medicine patients. Radiat Res 178(5):481-8.

Herrmann K, Erkan M, Dobritz M, Schuster T, Siveke JT, Beer AJ, Wester HJ, Schmid RM, Friess H, Schwaiger M, Kleeff J, Buck AK. (2012) Comparison of 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours. Eur J Nucl Med Mol Imaging    39(5):846-51.

Kreissl MC, Hänscheid H, Löhr M, Verburg FA, Schiller M, Lassmann M, Reiners C, Samnick SS, Buck AK, Flentje M, Sweeney RA. (2012) Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiat Oncol 7:99.

Li Z, Graf N, Herrmann K, Jünger A, Aichler M, Feuchtinger A, Baumgart A, Walch A, Peschel C, Schwaiger M, Buck A, Keller U, Dechow T. (2012) FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy. Cancer Res 72(19):5014-24.

Morbach H, Schneider P, Schwarz T, Hofmann C, Raab P, Neubauer H, Düren C, Beer M, Girschick HJ. (2012) Comparison of magnetic resonance imaging and 99mTechnetium-labelled methylene diphosphonate bone scintigraphy in the initial assessment of chronic non-bacterial osteomyelitis of childhood and adolescents. Clin Exp Rheumatol 30(4):578-82.

Schneider R, Schneider M, Reiners C, Schneider P. (2012) Effects of levothyroxine on bone mineral density, muscle force, and bone turnover markers: a cohort study. J Clin Endocrinol Metab 97(11)3926-34.

Spallek L, Krille L, Reiners C, Schneider R, Yamashita S, Zeeb H. (2012) Adverse effects of iodine thyroid blocking: a systematic review. Radiat Prot Dosimetry 150(3):267-77.

Verburg FA, Grelle I, Giovanella L, Reiners C. (2012) Evaluation of the BRAHMS KRYPTOR thyroglobulin "mini-recovery" test in thyroid healthy subjects. Horm Metab Res 44(7):555-7.

Verburg FA, Smit JW, Grelle I, Visser TJ, Peeters RP, Reiners C. (2012) Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.  Clin Endocrinol (Oxf) 76(4):577-81.

Zahn RK, Frey S, Jakubietz RG, Jakubietz MG, Doht S, Schneider P, Waschke J, Meffert RH. (2012) A contoured locking plate for distal fibular fractures in osteoporotic bone: a biomechanical cadaver study. Injury 43(6):718-25.

Publikationen 2011

Al-Ibraheem A, Bundschuh RA, Notni J, Buck A, Winter A, Wester HJ, Schwaiger M, Scheidhauer K. (2011) Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours? Eur J Nucl Med Mol Imaging 38(11):2005-13.

Biko J, Reiners C, Kreissl MC, Verburg FA, Demidchik Y, Drozd V. (2011) Favourable course of disease after incomplete remission on (131)I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up. Eur J Nucl Med Mol Imaging 38(4):651-5.

Chen DY, Schneider PF, Zhang XS, He ZM, Jing J, Chen TH. (2011) Striving for euthyroidism in radioiodine therapy of Graves' disease: a 12-year prospective, randomized, open-label blinded end point study. Thyroid 21(6):647-54.

Chiesa C, Lassmann M. (2011) Dosimetry in nuclear medicine therapy. Q J Nucl Med Mol Imaging 55(1):2-4.

Dainiak N, Gent RN, Carr Z, Schneider R, Bader J, Buglova E, Chao N, Coleman CN, Ganser A, Gorin C, Hauer-Jensen M, Huff LA, Lillis-Hearne P, Maekawa K, Nemhauser J, Powles R, Schünemann H, Shapiro A, Stenke L, Valverde N, Weinstock D, White D, Albanese J, Meineke V. (2011) First global consensus for evidence-based management of the hematopoietic syndrome resulting from exposure to ionizing radiation. Disaster Med Public Health Prep 5(3):202-12.

Dainiak N, Gent RN, Carr Z, Schneider R, Bader J, Buglova E, Chao N, Coleman CN, Ganser A, Gorin C, Hauer-Jensen M, Huff LA, Lillis-Hearne P, Maekawa K, Nemhauser J, Powles R, Schünemann H, Shapiro A, Stenke L, Valverde N, Weinstock D, White D, Albanese J, Meineke V. (2011) Literature review and global consensus on management of acute radiation syndrome affecting nonhematopoietic organ systems. Disaster Med Public Health Prep 5(3):183-201.

Eberlein U, Bröer JH, Vandevoorde C, Santos P, Bardiès M, Bacher K, Nosske D, Lassmann M. (2011) Biokinetics and dosimetry of commonly used radiopharmaceuticals in diagnostic nuclear medicine - a review. Eur J Nucl Med Mol Imaging 38(12):2269-81.

Foryst-Ludwig A, Kreissl MC, Sprang C, Thalke B, Böhm C, Benz V, Gürgen D, Dragun D, Schubert C, Mai K, Stawowy P, Spranger J, Regitz-Zagrosek V, Unger T, Kintscher U. (2011) Sex differences in physiological cardiac hypertrophy are associated with exercise-mediated changes in energy substrate availability. Am J Physiol Heart Circ Physiol 301(1):H115-22.

Frank-Raue K, Ganten M, Kreissl MC, Raue F. (2011) Rapid response to sorafenib in metastatic medullary thyroid carcinoma. Exp Clin Endocrinol Diabetes 119(3):151-5.

Giovanella L, Suriano S, Castellani M, Ceriani L, Verburg FA. (2011) Thyroid remnant estimation by Tc-99m-sestamibi scanning predicts the effectiveness of rhTSH-stimulated I-131 ablation in patients with differentiated thyroid carcinoma. Clin Nucl Med 36(9):781-5.

Giovanella L, Suriano S, Ceriani L, Verburg FA. (2011) Undetectable thyroglobulin in patients with differentiated thyroid carcinoma and residual radioiodine uptake on a postablation whole-body scan. Clin Nucl Med 36(2):109-12.

Giovanella L, Suriano S, Ricci R, Ceriani L, Anton Verburg F. (2011) Postsurgical thyroid remnant estimation by (??m) Tc-pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma. Head Neck 33(4):552-6.

Graf H, Fast S, Pacini F, Pinchera A, Leung A, Vaisman M, Reiners C, Wemeau JL, Huysmans D, Harper W, Driedger A, de Souza HN, Castagna MG, Antonangeli L, Braverman L, Corbo R, Düren C, Proust-Lemoine E, Edelbroek MA, Marriott C, Rachinsky I, Grupe P, Watt T, Magner J, Hegedus L. (2011) Modified-release recombinant human TSH (MRrhTSH) augments the effect of (131)I therapy in benign multinodular goiter: results from a multicenter international, randomized, placebo-controlled study. J Clin Endocrinol Metab 96(5):1368-76.

Grussendorf M, Reiners C, Paschke R, Wegscheider K, LISA Investigators. (2011) Reduction of thyroid nodule volume by levothyroxine and iodine alone and in combination: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 96(9):2786-95.

Hänscheid H, Lassmann M, Reiners C. (2011) Dosimetry prior to I-131-therapy of benign thyroid disease. Z Med Phys 21(4):250-7.

Hänscheid H, Reiners C, Goulko G, Luster M, Schneider-Ludorff M, Buck AK, Lassmann M. (2011) Facing the nuclear threat: thyroid blocking revisited. J Clin Endocrinol Metab    96(11):3511-6.

Hänscheid H, Verburg FA, Biko J, Diessl S, Demidchik YE, Drozd V, Reiners C. (2011) Success of the postoperative 131I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin level. Eur J Nucl Med Mol Imaging 38(7):1296-302.

Hebestreit H, Biko J, Drozd V, Demidchik Y, Burkhardt A, Trusen A, Beer M, Reiners C. (2011) Pulmonary fibrosis in youth treated with radioiodine for juvenile thyroid cancer and lung metastases after Chernobyl. Eur J Nucl Med Mol Imaging 38(9):1683-90.

Herrmann K, Benz MR, Krause BJ, Pomykala KL, Buck AK, Czernin J. (2011) (18)F-FDG-PET/CT in evaluating response to therapy in solid tumors: where we are and where we can go. Q J Nucl Med Mol Imaging 55(6):620-32.

Herrmann K, Buck AK, Schuster T, Junger A, Wieder HA, Graf N, Ringshausen I, Rudelius M, Wester HJ, Schwaiger M, Keller U, Dechow T. (2011) Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. J Nucl Med 52(5):690-6.

Herrmann K, Buck AK, Schuster T, Rudelius M, Wester HJ, Graf N, Scheuerer C, Peschel C, Schwaiger M, Dechow T, Keller U. (2011) A pilot study to evaluate 3'-deoxy-3'-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma. J Nucl Med 52(12):1898-902.

Israel I, Blass G, Reiners C, Samnick S. (2011) Validation of an amino-acid-based radionuclide therapy plus external beam radiotherapy in heterotopic glioblastoma models. Nucl Med Biol 38(4)451-60.

Kratzsch J, Petzold A, Raue F, Reinhardt W, Bröcker-Preuss M, Görges R, Mann K, Karges W, Morgenthaler N, Luster M, Reiners C, Thiery J, Dralle H, Fuhrer D. (2011) Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer. Clin Chem 57(3):467-74.

Lassmann M, Chiesa C, Flux G, Bardiès M, EANM Dosimetry Committee , Bacher K, Bardiès M, Chiesa C, Flux G, Konijnenberg M, Lassmann M, Palm S, Strand SE, Strigari L. (2011) EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging 38(1):192-200.

Lassmann M, Hänscheid H, Verburg FA, Luster M. (2011) The use of dosimetry in the treatment of differentiated thyroid cancer. Q J Nucl Med Mol Imaging 55(2):107-15.

Reiners C, Hänscheid H, Luster M, Lassmann M, Verburg FA. (2011) Radioiodine for remnant ablation and therapy of metastatic disease. Nat Rev Endocrinol 7(10):589-95.

Rivkees SA, Mazzaferri EL, Verburg FA, Reiners C, Luster M, Breuer CK, Dinauer CA, Udelsman R. (2011) The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy. Endocr Rev 32(6):798-826.

Schmid KW, Reiners C. (2011) When is thyroid fine-needle biopsy most effective? Pathologe 32(2):169-72.

Schneider P, Schwab M, Hänscheid H. (2011) Identification of factors associated with risk of fall using a force platform and power spectrum analysis technique. J Biomech 44(10):2008-12.

Verburg FA, Biko J, Diessl S, Demidchik Y, Drozd V, Rivkees SA, Reiners C, Hänscheid H. (2011) I-131 activities as high as safely administrable (AHASA) for the treatment of children and adolescents with advanced differentiated thyroid cancer. J Clin Endocrinol Metab 96(8):E1268-71.

Verburg FA, Kirchgässner C, Hebestreit H, Steigerwald U, Lentjes EG, Ergezinger K, Grelle I, Reiners C, Luster M. (2011) Reference ranges for analytes of thyroid function in children. Horm Metab Res 43(6):422-6.

Verburg FA, Lassmann M, Mäder U, Luster M, Reiners C, Hänscheid H. (2011) The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients. Eur J Nucl Med Mol Imaging 38(4):673-80.

Verburg FA, Luster M, Lassmann M, Reiners C. (2011) (131)I therapy in patients with benign thyroid disease does not conclusively lead to a higher risk of subsequent malignancies. Nuklearmedizin 50(3):93-9;quiz N20.

Verburg FA, Reiners C. (2011) Continuous re-evaluation in differentiated thyroid carcinoma. Nat Rev Endocrinol 7(3):127-8.

Willhauck MJ, Schott M, Kreissl MC, Fassnacht M, Spitzweg C. (2011) New therapeutic options for advanced thyroid cancer. Dtsch Med Wochenschr 136(22):1165-8.

Zahn RK, Frey S, Moritz M, Waschke J, Schneider P, Meffert RH. (2011) Supination external rotation lesions of the ankle joint in osteoporotic lower leg specimens: Experimental induction and review of the literature. Unfallchirurg 114(8):697-704.

Kontakt, Öffnungszeiten, Sprechzeiten

Öffnungszeiten der Ambulanzen:

Montag bis Freitag

Schilddrüse: 8:00 Uhr bis 16:00 Uhr

PET: 7:00 Uhr bis 16:00 Uhr

Sonstige: 8:00 Uhr bis 16:00 Uhr


Poliklinik Aufnahme:
+49 931 201-35100

Ute Dausacker, Barbara Hilber:
+49 931 201-35001

Prof. Dr. Andreas K. Buck



Prof. Dr. Andreas Buck:

+49 931 201-635000


Klinik und Poliklinik für Nuklearmedizin des Universitätsklinikums Zentrum Innere Medizin (ZIM) | Oberdürrbacher Straße 6 | Haus A4 | 97080 Würzburg | Deutschland